Shepherd Financial Partners LLC Acquires 258 Shares of Zoetis Inc. (NYSE:ZTS)

Shepherd Financial Partners LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,555 shares of the company’s stock after acquiring an additional 258 shares during the quarter. Shepherd Financial Partners LLC’s holdings in Zoetis were worth $1,672,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after buying an additional 414,605 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Zoetis by 4.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after buying an additional 178,303 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of Zoetis by 2.3% in the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock valued at $685,416,000 after buying an additional 90,330 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after buying an additional 166,517 shares during the last quarter. Finally, Sarasin & Partners LLP lifted its holdings in Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after purchasing an additional 1,904,899 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 1.2 %

Shares of NYSE ZTS traded up $2.22 during trading on Friday, hitting $181.00. The stock had a trading volume of 706,699 shares, compared to its average volume of 2,497,873. The firm has a fifty day moving average of $188.95 and a two-hundred day moving average of $178.28. The company has a market capitalization of $82.00 billion, a PE ratio of 34.99, a PEG ratio of 2.84 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business posted $1.41 earnings per share. As a group, equities research analysts forecast that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.95%. Zoetis’s dividend payout ratio is presently 33.86%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.